Create a new standard of care for a large spectrum of heart failure patients by introducing breakthrough implantable circulatory support solutions that restore a normal life with minimal side effects.
CorWave is a high-growth company founded in 2011 by the incubator MD Start and supported by renowned investors. We raised more than 35 million euros in funding, and the company employs more than 50 people.
CorWave has won numerous awards and competitions. In 2016 CorWave won phase 1 of the Worldwide Innovation Challenge (Concours Mondial d’Innovation – CMI) for the NovaPulse project. In 2017, this project also won phase 2 of the CMI competition. In the same year, CorWave received the Deloitte Technology Fast 50 Biotech Future Award and in 2018 a grant for the Calypso project as part of the Program d’Investissements d’Avenir (PIA) operated by Bpifrance.
Invention of wave membrane technology by Jean-Baptiste Drevet, he collaborates with the CNRS and creates AMS R&D
Creation of the company CorWave SAS by the incubator MD Start and exclusive license agreement with AMS R&D
CorWave joins Agoranov Incubator
First presentation at a scientific congress of cardiac surgery
€ 3.3M in Series A financing
CorWave joins Paris Biotech Santé incubator
Participates in the Worldwide Innovation Challenge, wins phase 1 for the NovaPulse project (Nemo development)
€15.5M in series B financing
Participates in the Worldwide Innovation Challenge, wins phase 2 for the NovaPulse project
Receives the Deloitte Technology Fast 50 Biotech Future award
CorWave joins BPI Hub HealthTech
Nominated for “Trophée des Futures Licornes” award
Receives Audience Award for SNITEM innovative start-ups
Receives a PSPC grant by BPI for the Calypso project
Selected among KPMG Tech Pulse 40 companies
Receives “Trophée de l’embarqué” award for healthcare category